These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1910891)

  • 21. Mass screening for colorectal cancer: compliance in Almopea Region.
    Chrissidis T; Saliangas K; Economou A; Nikoloudis N; Andreadis E; Prodromou K; Georgakis K
    Tech Coloproctol; 2004 Nov; 8 Suppl 1():s193-5. PubMed ID: 15655620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colorectal cancer screening compliance by medicine residents: perceived and actual.
    Zack DL; DiBaise JK; Quigley EM; Roy HK
    Am J Gastroenterol; 2001 Oct; 96(10):3004-8. PubMed ID: 11693339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screen compliance rates in 14-years annual screening program for colorectal cancer with immunochemical fecal occult blood test-- identification of higher priority subjects in health education.
    Wei N; Nakama H; Li T
    Eur J Med Res; 1998 Jul; 3(7):341-4. PubMed ID: 9682030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colorectal cancer screening by primary care physicians in two medical care organizations.
    Hawley ST; Levin B; Vernon SW
    Cancer Detect Prev; 2001; 25(3):309-18. PubMed ID: 11425273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
    Musil D; Tillich J
    Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Physicians' reminders promote annual fecal occult blood testing compliance].
    Vinker S; Shumla V; Kitai E
    Harefuah; 2000 Jun; 138(12):1019-21, 1088, 1087. PubMed ID: 10979422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary care patients' understanding of colorectal cancer screening.
    Greisinger A; Hawley ST; Bettencourt JL; Perz CA; Vernon SW
    Cancer Detect Prev; 2006; 30(1):67-74. PubMed ID: 16458449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
    Inadomi JM
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S198-204. PubMed ID: 19120898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fecal occult blood testing for colorectal cancer screening: use the finger.
    Burke CA; Tadikonda L; Machicao V
    Am J Gastroenterol; 2001 Nov; 96(11):3175-7. PubMed ID: 11721767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs.
    El-Serag HB; Petersen L; Hampel H; Richardson P; Cooper G
    Arch Intern Med; 2006 Nov; 166(20):2202-8. PubMed ID: 17101937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Digital fecal occult blood testing in the ambulatory urology clinic.
    Goetzl MA; Outman JE; Griebling TL; Holzbeierlein JM; Weigel JW; Thrasher JB
    J Am Coll Surg; 2008 Jan; 206(1):144-7. PubMed ID: 18155580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns and predictors of colorectal cancer test use in the adult U.S. population.
    Seeff LC; Nadel MR; Klabunde CN; Thompson T; Shapiro JA; Vernon SW; Coates RJ
    Cancer; 2004 May; 100(10):2093-103. PubMed ID: 15139050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of self-reported colorectal cancer screening behavior from a mixed-mode survey of veterans.
    Partin MR; Grill J; Noorbaloochi S; Powell AA; Burgess DJ; Vernon SW; Halek K; Griffin JM; van Ryn M; Fisher DA
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):768-76. PubMed ID: 18381474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colorectal carcinoma screening procedure use among primary care patients.
    Lafata JE; Williams LK; Ben-Menachem T; Moon C; Divine G
    Cancer; 2005 Oct; 104(7):1356-61. PubMed ID: 16092119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial.
    Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Church T; Yurgalevitch S; Austin JH; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Jul; 97(13):989-97. PubMed ID: 15998952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal occult blood testing: clinical value and limitations.
    Simon JB
    Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer.
    Lindholm E; Brevinge H; Haglind E
    Br J Surg; 2008 Aug; 95(8):1029-36. PubMed ID: 18563785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of comorbidity on colorectal cancer screening in the veterans healthcare system.
    Fisher DA; Galanko J; Dudley TK; Shaheen NJ
    Clin Gastroenterol Hepatol; 2007 Aug; 5(8):991-6. PubMed ID: 17627900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.